8-K: Eli Lilly Raises $6.75B in Multi-Tranche Debt Offering

Eli Lilly and Company successfully completed a multi-tranche debt offering, raising approximately $6.71 billion in net proceeds through the issuance of fixed and floating rate notes.

Summary

• Eli Lilly and Company entered into an underwriting agreement on August 18, 2025, for the issuance and sale of $6.75 billion in aggregate principal amount of debt securities.
• The offering includes seven series of notes: Floating Rate Notes due 2028 ($750 million), 4.000% Notes due 2028 ($1 billion), 4.250% Notes due 2031 ($750 million), 4.550% Notes due 2032 ($1 billion), 4.900% Notes due 2035 ($1.25 billion), 5.550% Notes due 2055 ($1 billion), and 5.650% Notes due 2065 ($1 billion).
• The Floating Rate Notes accrue interest at Compounded SOFR plus 0.530%, reset quarterly, and are not redeemable prior to maturity.
• The Fixed Rate Notes bear interest ranging from 4.000% to 5.650% per annum, payable semi-annually, and are redeemable at the company's option at specified make-whole or par call prices.
• The closing of the offering occurred on August 20, 2025, resulting in net proceeds of approximately $6.71 billion after underwriting discounts and before estimated offering expenses.
• All notes are unsecured and unsubordinated obligations of the company, ranking equally with other existing and future unsecured and unsubordinated indebtedness.
• The notes are issued under an Indenture dated February 1, 1991, with Deutsche Bank Trust Company Americas as trustee.

Sentiment

Score: 7

Explanation: The filing details a successful, large-scale debt offering, which provides significant capital and financial flexibility to the company. While it increases debt, it's a standard financing activity for a healthy company, indicating access to capital markets on favorable terms. The diversification of debt maturities and inclusion of SOFR-linked notes are positive aspects of financial management.

Positives

• Successfully raised a significant amount of capital, approximately $6.71 billion, enhancing financial flexibility.
• Diversified debt maturity profile with notes maturing from 2028 to 2065, providing long-term financing.
• The offering includes both fixed and floating rate notes, allowing for a balanced approach to interest rate risk management.

Negatives

• The issuance of new debt increases the company's overall leverage and interest expense burden.
• Floating Rate Notes introduce interest rate volatility risk, as interest payments can fluctuate based on Compounded SOFR.

Risks

• The amount of interest payable on Floating Rate Notes is set once per period and determined near the end of the relevant Interest Period, making it difficult for holders to reliably estimate total interest until shortly prior to payment.
• Floating Rate Notes interest rates may be volatile, potentially leading to a decline in interest receipts and market price.
• Factors affecting market rates, including geopolitical, economic, financial, political, regulatory, and judicial events, are beyond the company's control.
• Historical levels, fluctuations, and trends of Compounded SOFR are not necessarily indicative of future levels, and past performance does not predict future performance.
• Changes in Compounded SOFR may not result in a comparable change in the market value of Floating Rate Notes.
• Investors may be unwilling or unable to trade Floating Rate Notes without changes to their information technology systems, which could adversely impact liquidity and trading price.
• SOFR has a limited history, and its future performance cannot be predicted based on this limited data.
• Any failure of SOFR to maintain market acceptance could adversely affect the value of Floating Rate Notes, as it does not measure bank-specific credit risk like LIBOR.
• SOFR may be more volatile than other market rates, and the return on Floating Rate Notes may fluctuate more than debt securities with less volatile rates.
• The specific formula for Compounded SOFR used for the Floating Rate Notes may not be widely adopted by other market participants, potentially affecting liquidity and market value.
• The SOFR Index may be modified or discontinued, leading to a different benchmark, which could adversely affect the value and return of Floating Rate Notes.
• The company or its designee has authority to make determinations, elections, calculations, and adjustments regarding the Floating Rate Notes, including in connection with a Benchmark Transition Event, which could involve discretion and subjective judgments and adversely affect note value and return.

Future Outlook

The filing details the terms of newly issued debt securities, providing long-term financing for the company. It outlines future interest payment schedules and maturity dates for each series of notes, extending out to 2065. The inclusion of floating rate notes linked to Compounded SOFR indicates an adaptation to evolving benchmark rates in the financial markets.

Management Comments

• Jon Haug, Senior Vice President, Treasurer and Corporate Finance and Investment Banking, and Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Secretary, certified the establishment and terms of the debt securities pursuant to the Indenture and Board Resolutions.

Industry Context

This debt offering by Eli Lilly and Company is a typical capital markets activity for a large pharmaceutical company, aimed at securing long-term funding for general corporate purposes, including potential R&D, acquisitions, or working capital. The use of SOFR-linked notes reflects a broader industry trend in financial markets transitioning away from LIBOR as a benchmark interest rate.

Comparison to Industry Standards

• The offering structure, including a mix of fixed and floating rate notes with various maturities, is consistent with capital raising strategies employed by other large, well-established companies in the pharmaceutical and biotechnology sectors.
• The interest rates and yields appear to be in line with prevailing market conditions for investment-grade corporate debt at the time of issuance, reflecting the company's creditworthiness.
• The transition to SOFR for floating rate instruments aligns with global financial industry efforts to adopt alternative reference rates following the discontinuation of LIBOR, a practice seen across various sectors for new debt issuances.

Corporate Governance

Stakeholder Impact

• Shareholders: The capital raise provides the company with additional funds for strategic initiatives, potentially supporting growth and long-term value creation, though it also increases the company's debt obligations.
• Creditors: New notes rank equally with existing unsecured and unsubordinated indebtedness, maintaining their relative position in the capital structure.
• Investors in the Notes: Will receive regular interest payments and principal repayment at maturity, subject to the terms and conditions of each note series, including redemption options for fixed-rate notes and interest rate adjustments for floating-rate notes.

Next Steps

• Regular semi-annual or quarterly interest payments will commence on the respective notes starting April 15, 2026, March 15, 2026, or January 15, 2026.
• The company may redeem Fixed Rate Notes, in whole or in part, at its option prior to their maturity dates based on specified redemption provisions.

Key Dates

Recommendation

The filing details a routine, albeit large, debt offering for Eli Lilly and Company. This action provides significant capital, which is generally positive for a company's operational and strategic flexibility. However, it does not present new information that would fundamentally alter the investment thesis for a seasoned investor. The terms of the debt appear standard for a company of Eli Lilly's stature, and the associated risks are typical for such instruments. Therefore, a 'hold' recommendation is appropriate, as this financing event supports ongoing operations without indicating a significant shift in the company's immediate prospects or valuation.

Keywords

Debt Offering, Notes, Bonds, Fixed Rate Notes, Floating Rate Notes, SOFR, Capital Raise, Corporate Finance, SEC Filing, Eli Lilly